October 20, 2017

Promising preliminary long-term data for WTX101 in Wilson Disease highlighted at The Liver Meeting®

Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial with WTX101 (bis-choline tetrathiomolybdate), an investigation...
Read more
October 19, 2017

BONESUPPORT HOLDING AB (publ) – Q3 2017 Interim Report – invitation to conference call and webcast

Lund, Sweden, 08:00 CEST 19 October 2017 – BONESUPPORT™ an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trau...
Read more
October 17, 2017

Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm

Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or the “Company”), a biotechnology com...
Read more
October 16, 2017

Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Esophageal Cancer

October 16, 2017—BOSTON, MA. and STOCKHOLM, SWEDEN, October 16, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticance...
Read more
October 16, 2017

Nexstim Plc is negotiating an assembly and distribution arrangement in China and a financing arrangement for the financing of its bring-to-market strategy in Europe and the US

Company announcement, Helsinki, 16 October 2017, at 9:00 am Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pi...
Read more
October 16, 2017

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

Paris, France, October 16, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovati...
Read more
October 12, 2017

Change in Nexstim Plc’s Management Team

12 October 2017 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a  medical  technology company developing and marketing pioneering navigated  non-invasive  brai...
Read more
October 12, 2017

Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer

Thursday, October 12, 2017 Oslo, Norway, 12 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-o...
Read more
October 6, 2017

Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology

Oct 06, 2017 Wilson Therapeutics (publ.) today announced that data from a Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper...
Read more
October 6, 2017

Strongbridge Biopharma plc Announces Closing of Public Offering of Ordinary Shares

DUBLIN, Ireland and TREVOSE, Pa., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced the closing of its previously...
Read more